The Changing Landscape of Psoriasis: New Horizons for Oral Therapies-Reference-Cited by-同舟云学术

The Changing Landscape of Psoriasis: New Horizons for Oral Therapies

Published:2018-08-09 Issue: Volume: Page:2-9
ISSN:2054-6211
Container-title:EMJ Dermatology
language:
Short-container-title:EMJ Dermatol

Author:

Battershill Anna¹

Affiliation:

1. ApotheCom, London, UK

Abstract

Prof Boehncke opened the symposium and highlighted the changing landscape of psoriasis management. On behalf of Prof Mrowietz, who was unable to attend, Prof Boehncke shared the evidence on fumarates in general and oral dimethyl fumarate (DMF) in particular. Dr Weisenseel closed the symposium by discussing the use of fumarates in current clinical practice.

Publisher

European Medical Group

Subject

General Medicine

Reference24 articles.

1. Saurat JH et al.; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-66.

2. Thaçi D et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400-9.

3. Gordon KB et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016; 375(4):345-56.

4. Vaidya TS et al. Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity. Dermatol Online J. 2015;21(9):14.

5. Nast A et al.; Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10(Suppl 2):S1-95.